
News
Filter Results
Displaying 301–310 of 504
-
Nov 7, 2019
AGTC Announces Development of Stargardt Disease Gene Therapy
Dual-vector delivery system designed to deliver the large ABCA4 gene
-
Oct 29, 2019
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Zimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
Oct 18, 2019
ReNeuron Reports Interim Results for Eight Patients with RP in Phase 2a Trial for Stem Cell Therapy
The Foundation funded earlier lab studies that made the clinical trial possible.
-
Oct 10, 2019
FDA Approves New Wet AMD Treatment that can be Administered Every Three Months
Beovu from Novartis reduces treatment burden for wet AMD patients
-
Oct 2, 2019
The program will offer patients with inherited retinal disease no-cost genetic testing and genetic counseling in the United States. Look for updated information on how to participate to be posted in mid-October, with program registration starting shortly thereafter.
-
Oct 1, 2019
AGTC Reports Promising Interim Results for XLRP and Achromatopsia Gene Therapy Trials
AGTC used Foundation’s My Retina Tracker registry to recruit patients for trials
-
Sep 24, 2019
Consortium Genetically Tests 40 Percent of People in Israel with IRDs
Patient benefits from genetic testing for IRDs include confirmation of their clinical diagnosis, identification of the disease inheritance pattern and risk for other family members, and determination of human studies for emerging therapies that may be appropriate for them.
-
Aug 16, 2019
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Aug 14, 2019
The treatment focuses on the P23H mutation in the RHO gene, which is the most prevalent variant causing adRP in the US and affects approximately 2,500 people.
-
Jul 25, 2019
Allergan and Editas Begin Recruiting for CRISPR/Cas9 Clinical Trial for LCA10
The trial will be the first for a CRISPR/Cas9 therapy administered inside the human body.